Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0
|
作者：
Dickinson, Michael [1 ,2 ]
Carlo-Stella, Carmelo [3 ,4 ]
Morschhauser, Franck [5 ,6 ]
Bachy, Emmanuel [7 ]
Corradini, Paolo [8 ,9 ]
Iacoboni, Gloria [10 ]
Khan, Cyrus [11 ]
Wrobel, Thomasz [12 ]
Offner, Fritz [13 ]
Trneny, Marek [14 ]
Wu, Shang-Ju [15 ]
Cartron, Guillaume [16 ]
Hertzberg, Mark [17 ,18 ]
Sureda, Anna [19 ]
Perez-Callejo, David [20 ]
Lundberg, Linda [20 ]
Relf, James [21 ]
Clark, Emma [21 ]
Humphrey, Kathryn [21 ]
Hutchings, Martin [22 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Humanitas Univ, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Milan, Italy
[5] Hop Claude Huriez, Lille, France
[6] CHU Lille, Lille, France
[7] Ctr Hosp Lyon Sud, Lyon, France
[8] Univ Milan, Milan, Italy
[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Allegheny Hlth Network, Pittsburgh, PA USA
[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland
[13] Univ Ziekenhuis Gent, Ghent, Belgium
[14] Charles Univ Hosp, Prague, Czech Republic
[15] Natl Taiwan Univ Hosp, Taipei, Taiwan
[16] CHU Montpellier, Montpellier, France
[17] Prince Wales Hosp, Sydney, NSW, Australia
[18] Univ New South Wales, Sydney, NSW, Australia
[19] Inst Catala Oncol Hosp, Barcelona, Spain
[20] F Hoffmann La Roche Ltd, Basel, Switzerland
[21] Roche Prod Ltd, Welwyn Garden City, Herts, England
[22] Rigshosp, Copenhagen, Denmark
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-478
引用
收藏
页码：S435 / S435
页数：1
相关论文
共 50 条
  • [21] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
    Crombie, Jennifer L.
    Jun, Monika
    Wang, Tongsheng
    Mutebi, Alex
    Wang, Anthony
    Chhibber, Anindit
    Kamalakar, Rajesh
    Ukropec, Jon
    Blaedel, Julie
    Kalsekar, Anupama
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1623 - 1633
  • [22] Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies
    Ayers, Emily C.
    Margolis, David
    Landsburg, Daniel J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10): : 661 - 667
  • [23] Tisagenlecleucel and Lisocabtagene Maraleucel: Comparative Efficacy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Prieto, Marcela Martinez
    Bollu, Vamsi
    Kuzan, David
    Maziarz, Richard
    Kersten, Marie Jose
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S380 - S381
  • [24] Predicting the risk of relapsed or refractory in patients with diffuse large B-cell lymphoma via deep learning
    Ma, Dongshen
    Yuan, Yuqing
    Miao, Xiaodan
    Gu, Ying
    Wang, Yubo
    Luo, Dan
    Fan, Meiting
    Shi, Xiaoli
    Xi, Shuxue
    Ji, Binbin
    Xiang, Chenxi
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [25] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [26] Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies
    Purdum, Anna
    Tieu, Ryan
    Reddy, Sheila R.
    Broder, Michael S.
    ONCOLOGIST, 2019, 24 (09): : 1229 - 1236
  • [27] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [28] Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Behnia, Sanaz
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda
    Smith, Stephen D.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 176 - 181
  • [29] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [30] ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
    Alderuccio, Juan Pablo
    Sharman, Jeff P.
    BLOOD REVIEWS, 2022, 56
12345